Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gotistobart
- Development stage
- Phase 3
- Lead developer
- BioNTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Gotistobart is a next-generation, pH-sensitive anti-CTLA-4 monoclonal antibody. It is designed to selectively deplete tumor-infiltrating regulatory T cells by preserving CTLA-4 recycling in peripheral tissues, aiming to enhance anti-tumor immunity while reducing immune-related adverse events. This mechanism differentiates it from other CTLA-4 inhibitors by potentially offering an improved therapeutic index. Gotistobart is being co-developed by BioNTech and OncoC4 for various oncology indications, with a primary focus on metastatic non-small cell lung cancer.
- Brand names
- gotistobart
- Other names
- 戈替妥巴
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on gotistobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gotistobart.